The SARS-CoV-2 Omicron (B. 1.1529) variant was designated as a variant of concern (VOC)
by the World Health Organization (WHO) on November 26, 2021. Within two months, it had …

ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …

Disclosures: C. Planchais reported a patent to PCT/EP2022/058777 licensed (SpikImm). I.
Fernández reported a patent to PCT/EP2022/058777 licensed (SpikImm). T. Bruel reported …

The Omicron subvariant BA. 2 has become the dominant circulating strain of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in many countries. Here, we have …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern
(VOCs), especially the latest Omicron, have exhibited severe antibody evasion. Broadly …

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
Omicron variant, sublineages BA. 1 and BA. 2, recently became the dominant variants of …

Emerging epidemiology data indicate that the Omicron BA. 2 sublineage is expected to
become the dominant strain owing to its enhanced transmissibility. 1 The BA. 1 sublineage …

The Omicron subvariant BA. 2 has become the dominant circulating strain of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in many countries. We have …

BNMFQWUHWYJTRI-BQFCYCMXSA-N 7-chloro-N-[(2S)-1-[[(1S)-1-cyano-2-[(3S)-2-
oxopiperidin-3-yl] ethyl] amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide …

The invention provides, in various embodiments, polypeptides (eg, camelid antibodies and
antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe …